BlackRock Health Sciences Term Trust (NYSE:BMEZ) Declares $0.18 Monthly Dividend

BlackRock Health Sciences Term Trust (NYSE:BMEZ) announced a monthly dividend on Friday, November 1st,NASDAQ Dividends reports. Shareholders of record on Friday, November 15th will be paid a dividend of 0.1769 per share on Friday, November 29th. This represents a $2.12 annualized dividend and a dividend yield of 13.51%. The ex-dividend date is Friday, November 15th.

BlackRock Health Sciences Term Trust has raised its dividend by an average of 20.7% per year over the last three years.

BlackRock Health Sciences Term Trust Stock Down 0.8 %

Shares of BMEZ stock traded down 0.13 on Wednesday, hitting 15.71. 152,763 shares of the stock were exchanged, compared to its average volume of 264,101. The business has a 50-day moving average of 15.80 and a 200 day moving average of 15.56. BlackRock Health Sciences Term Trust has a fifty-two week low of 13.41 and a fifty-two week high of 16.59.

Insider Activity

In other news, major shareholder Saba Capital Management, L.P. bought 29,795 shares of the stock in a transaction dated Wednesday, October 16th. The shares were bought at an average price of 15.81 per share, for a total transaction of 471,058.95. Following the completion of the purchase, the insider now owns 20,750,913 shares in the company, valued at approximately 328,071,934.53. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders acquired a total of 99,630 shares of company stock valued at $1,585,113 over the last three months.

BlackRock Health Sciences Term Trust Company Profile

BlackRock Health Sciences Trust II’s (BMEZ) (the ‘Trust’) investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries.